LEXICON PHARMACEUTICALS, INC. Amortization of Intangible Assets
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Amortization of Intangible Assets of $300.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2020-10-30
- LEXICON PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2020-09-30 was $300.00K, a 25.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2019-09-30 was $400.00K, a 0.00% change year-over-year.
- LEXICON PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2019-06-30 was $500.00K, a 0.00% change year-over-year.
- LEXICON PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2019-03-31 was $400.00K, a 0.00% change year-over-year.
- LEXICON PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2018 was $1.80M, a 20.00% increase from fiscal 2017.
- LEXICON PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2017 was $1.50M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2020-09-30 | $300.00K 10-Q · filed 2020-10-30 | $1.20M 10-Q · filed 2020-10-30 | ||
| 2019-09-30 | $400.00K 10-Q · filed 2020-10-30 | $900.00K derived: sum of 2 quarters · filed 2020-10-30 | $1.30M 10-Q · filed 2020-10-30 | $1.80M derived: sum of 4 quarters · filed 2020-10-30 |
| 2019-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $900.00K 10-Q · filed 2019-08-01 | $1.40M derived: sum of 3 quarters · filed 2019-08-01 | $1.80M derived: sum of 4 quarters · filed 2019-08-01 |
| 2019-03-31 | $400.00K 10-Q · filed 2019-05-01 | $900.00K derived: sum of 2 quarters · filed 2019-05-01 | $1.30M derived: sum of 3 quarters · filed 2019-05-01 | $1.80M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $900.00K derived: sum of 2 quarters · filed 2019-03-15 | $1.40M derived: sum of 3 quarters · filed 2019-08-01 | $1.80M 10-K · filed 2019-03-15 |
| 2018-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $900.00K derived: sum of 2 quarters · filed 2019-08-01 | $1.30M 10-Q · filed 2018-11-01 | $1.80M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $900.00K 10-Q · filed 2019-08-01 | $1.40M derived: sum of 3 quarters · filed 2019-08-01 | $1.80M derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | $400.00K 10-Q · filed 2018-05-03 | $900.00K derived: sum of 2 quarters · filed 2019-03-15 | $1.30M derived: sum of 3 quarters · filed 2019-03-15 | $1.70M derived: sum of 4 quarters · filed 2019-03-15 |
| 2017-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $900.00K derived: sum of 2 quarters · filed 2019-03-15 | $1.30M derived: sum of 3 quarters · filed 2019-03-15 | $1.50M 10-K · filed 2019-03-15 |
| 2017-09-30 | $400.00K 10-Q · filed 2017-11-08 | $800.00K derived: sum of 2 quarters · filed 2017-11-08 | $1.00M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $400.00K 10-Q · filed 2017-08-01 | $600.00K 10-Q · filed 2018-07-30 | ||
| 2017-03-31 | $100.00K 10-Q · filed 2018-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |